Cite

HARVARD Citation

    McCall, D. et al. (2023). Mini‐hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B‐acute lymphoblastic leukemia. Pediatric blood & cancer. 70 (1), p. n/a. [Online]. 
  
Back to record